Abbott Laboratories (ABT) Analyst Ratings & Price Targets

Abbott Laboratories

ABT · NYSE

Analyst Consensus

Buy

20 analysts

$106

Current

—

Low

$119

Average

—

High

Average target implies +12.10% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 20 analysts, with a mean price target of $118.5. No low or high target is reported, so the width of the target range and where targets cluster cannot be measured from the available figures. The evidence does not name the most bullish or least bullish analyst, identify any target revisions during the past week, or record a substantive disagreement behind the target distribution. It likewise provides no firm-specific rating changes to explain the consensus. The actionable conclusion from the dataset is therefore the breadth of the Buy consensus, not its dispersion, recent direction, or analyst-level rationale.

Rating Actions

No individual rating actions have been captured for ABTyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BTIG

CITIGROUP

CO FORECST

EDWARD JONES

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

WELLS FARGO SEC

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: ABT
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

Abbott (NYSE: ABT) is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic 3 medicines. Our 122,000 colleagues serve people in more than 160 countries. Together with our foundation, Abbott Fund, we partner with trusted organizations to build programs that strengthen care, improve access and help families and communities thrive. We're committed to building a healthier future by inspiring lifelong habits that support well-being and help to prevent chronic disease for generations to come.

Key Issues

Bullish view

Abbott’s revenue rises to $44.3 billion in fiscal 2025 from $42.0 billion in fiscal 2024, indicating continued top-line expansion across its businesses.

Bearish view

Net income falls to $6.5 billion from $13.4 billion over the same period, so the available figures do not show that revenue growth is translating into stronger profitability.

Analyst Consensus

See all

Buy